Conclusion: Given the pivotal role of FAM174B in shaping the non-inflamed tumor microenvironment of BLCA, therapeutic targeting of FAM174B may represent a promising strategy for BLCA management. Here, FAM174B is linked to bladder transitional cell carcinoma.